Stockreport

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 f...

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible f [Read more]